Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS
Hagens Berman issued a shareholder-solicitation notice regarding Regeneron, alleging securities violations related to the failed Phase 3 trial of Fianlimab in combination with Libtayo. The lawsuit claims Regeneron made false statements about the trial protocol and primary endpoint progression-free survival, leading to a sharp decline in share price.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.